Compare MAGN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | RCKT |
|---|---|---|
| Founded | 1864 | 1999 |
| Country | United States | United States |
| Employees | 8500 | 202 |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 401.6M |
| IPO Year | N/A | N/A |
| Metric | MAGN | RCKT |
|---|---|---|
| Price | $13.52 | $3.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $12.00 | ★ $29.73 |
| AVG Volume (30 Days) | 314.5K | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | $3.47 | $64.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.82 | $2.53 |
| 52 Week High | $15.52 | $5.45 |
| Indicator | MAGN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 48.64 |
| Support Level | $13.15 | $3.36 |
| Resistance Level | $15.24 | $3.56 |
| Average True Range (ATR) | 0.63 | 0.24 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 64.44 | 20.09 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.